There’s a mantra that gets repeated by everyone around me: biotech is the next big thing. I’m willing to believe that on average the biotech industry will probably grow faster than the market, maybe even faster than the tech industry over the next 20 or 30 years. What I’m less enthused by is the prospect of trying to pick and invest in the winners of that market and not get stuck holding the losers. I feel like biotech in general will have a much larger standard deviation on its returns, a small number of companies will make out like bandits and a very very large number of companies will make nothing. This is generally true in most markets, but in biotech you have the added barrier of the government to think about.
When a tech company brings a new product to market, they will design it, test it, then try to sell it to consumers. But when a biotech company brings a new product to market, they often have an added hurdle of the government. They need to design a product, test it, ask the government for permission to sell it, and then sell it to consumers. These consumers are usually healthcare patients because the product is usually a drug or medical device. The government in this case is protecting us from bad products in healthcare, but in turn this puts up a barrier to entry that ensures that only a few products get through and get all the money in the market. There’s a large market for crappy but cheap smartphones that retail for far less than an iPhone or an Android, there isn’t any market for crap drugs that only “sort of” cure your disease.
50 years ago biotech’s second biggest area was agribusiness, but today all the biggest movers and shakers are all related to medical in some way. Everyone is working in an industry where money only comes in if you can improve the health of a patient. Even the non-medical companies, the “shovel salesmen” in the biotech gold rush, the products they sell will only get bought by companies which are themselves trying to make a drug or a device that will prolong the life of a patient. So I feel like any biotech giant I wanted to invest in, be it Pfizer or Merck or Johnson and Johnson, investing in any one of them is like playing a crap shoot with the FDA. If Pfizer’s next biggest drugs don’t get approval, Pfizer’s stock will go way down. And if the FDA approves a “better Tylenol” for mass market, then Johnson and Johnson could drop. So biotech feels like I’m investing in the future of the FDA more than I am the future of the market.
And then there’s Thermo Fisher, the biggest shovel salesman of the biotech gold rush. They make the products used in labs all over the world,I know even my lab uses a lot of Thermo Fisher brand products. Even here the future seems less certain than it is for say Amazon or Google because all the labs which buy Thermo Fisher products are still at the whims of the FDA. Everyone buys polypropylene tubes from Thermo Fisher, but what if the FDA decides polypropylene leaves behind microplastics which harm patients and mandates that polypropylene never be used in medical devices or drug manufacturing? Then Thermo and every company like them would be scrambling for a substitute, and there’s no way of predicting that Thermo would come out of that mess the victor. So shovel salesmen make for safer but by no means safe bets.
And finally there’s the small players in biotech, the startups and mid-sized companies which hope to build the products of the future. They are the most speculative companies of then all because they’re often pre-revenue companies which are hoping that whatever drug or device they own the IP for can get through the FDA’s hurdles and reach the mass market. These hurdles are very high and there’s no money in only getting past the first few just to fall at the last one. So when you invest in a company like that you’re investing in a business of hope and hype, and since even the greatest experts in biotechnology can’t predict which drug or device will work for patients there’s little chance of someone like me making all the right predictions.
So I guess biotech might be the future, but the future is too murky to invest in. I’d keep my money in biotech ETFs and hope for the best.